ID
25057
Descripción
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: PGx-Pharamacogenetic research.
Palabras clave
Versiones (2)
- 25/8/17 25/8/17 -
- 8/9/17 8/9/17 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
25 de agosto de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
PGx-Pharamacogenetic research GSK study Dyskinesia in Parkinson's disease NCT00363727
PGx-Pharamacogenetic research study Dyskinesia in Parkinson's disease NCT00363727
Descripción
Consent for PGx-Pharamacogenetic research
Descripción
The question "Has informed consent been obtained for PGx-Pharmacogenetic research?" should be completed at either Visit 6, Early Withdrawal, or Follow-Up Visit. If the question is answered No, check one box for reason and do not complete the remainder of the page.
Tipo de datos
boolean
Descripción
date consent PGx-Pharmacogenetic research
Tipo de datos
date
Descripción
reason consent unavailable
Tipo de datos
text
Descripción
reason consent unavailable specification
Tipo de datos
text
Descripción
Blood sample collection (DNA)
Descripción
Withdrawal of consent
Descripción
The question "Has the subject withdrawn consent for PGx-Pharmacogenetic research?" must be completed immediately if the subject withdraws consent. Otherwise, it must be completed when the subject leaves the study. It must be completed for all subjects for whom informed consent was obtained for PGx-Pharmacogenetic research. If consent is withdrawn, a request for destruction must be made and Blood Sample Destruction section below completed.
Tipo de datos
boolean
Descripción
Blood sample destruction
Descripción
Do not complete this section if a blood sample was not collected. The question "Has a request been made for sample destruction?" must be completed immediately if there is a request for sample destruction. Otherwise, it must be completed when the subject leaves the study. It must be completed for all subjects for whom a blood sample was obtained for PGx-Pharmacogenetic research.
Tipo de datos
boolean
Descripción
Blood sample destruction reason
Tipo de datos
text
Descripción
Blood sample destruction reason specification
Tipo de datos
text